ZIRCON-X was designed as a post-hoc analysis of imaging data collected in the ZIRCON trial to evaluate how the incorporation of 89 Zr-girentuximab PET imaging could influence clinical management ...

Scans that make prostate cancer cells glow can eliminate the need for invasive biopsies and cut false positive—and they're ...

Profound Medical (PROF) announced superiority on the prespecified, primary safety endpoint in the Level 1 post-market CAPTAIN randomized controlled trial comparing the TULSA Procedure with robotic ...

The median fraction of the gland reaching ablative temperatures on intra-procedural MRI thermometry was 78% (IQR 71-85), with 68% of cases comprising whole gland ablation and 32% sub-total ablation: ...

Esaote presents its new and innovative technology dedicated to urology: the exclusive Prostate Attention Map (PAM), now ...

Discusses First Clinical Outcomes and Precision of TULSA from the CAPTAIN Trial in Prostate Cancer March 13, 2026 11:30 ...

Australian scientists say it could also help reduce the risk of overdiagnosis by determining which cancers are low-risk and ...

First multicenter, randomized controlled trial directly comparing a new technology to robotic RP for men with localized prostate cancer to ...

Esaote Group, a leading Italian innovator in medical imaging - ultrasound, dedicated magnetic resonance and medical IT, is ...

Prostate cancer is one of the most common cancers affecting men around the world. It develops in the prostate, a small gland ...

A scan that makes prostate cancer cells “glow” could halve the number of men needing invasive biopsies, research suggests.

First results of the PRIMARY2 randomized phase III trial support consideration of PSMA PET/CT in diagnostic work-up ...